Overview
Gorlin-Chaudhry-Moss syndrome (GCM syndrome) is an extremely rare genetic disorder characterized by a distinctive combination of craniofacial, ocular, dental, and skeletal abnormalities along with hypertrichosis (excessive hair growth). The condition was first described by Gorlin, Chaudhry, and Moss in 1960. Key clinical features include coronal craniosynostosis (premature fusion of skull sutures), midface hypoplasia (underdevelopment of the middle portion of the face), patent ductus arteriosus or other congenital heart defects, eye anomalies such as microphthalmia (abnormally small eyes) and lid colobomas, hypoplasia of the labia majora, and dental anomalies including hypodontia and microdontia. Affected individuals typically present with short stature and generalized hypertrichosis, which is often one of the most noticeable features. The syndrome affects multiple body systems including the craniofacial skeleton, eyes, teeth, cardiovascular system, skin, and external genitalia. Intelligence is generally reported as normal in affected individuals, though developmental delays have been noted in some cases. The condition has been linked to mutations in the SLC25A24 gene, which encodes a mitochondrial carrier protein involved in energy metabolism. This gene plays a role in calcium-dependent mitochondrial transport, and its dysfunction is thought to contribute to the multisystem manifestations observed in this syndrome. There is currently no cure for Gorlin-Chaudhry-Moss syndrome, and management is symptomatic and supportive. Treatment typically involves a multidisciplinary approach including craniofacial surgery for craniosynostosis, cardiac surgery if congenital heart defects are present, ophthalmologic management for eye abnormalities, and dental interventions. Genetic counseling is recommended for affected families. Due to the extreme rarity of this condition, only a small number of cases have been reported in the medical literature, making comprehensive understanding of the natural history and optimal management strategies challenging.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Gorlin-Chaudhry-Moss syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Gorlin-Chaudhry-Moss syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Gorlin-Chaudhry-Moss syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Gorlin-Chaudhry-Moss syndrome.
Community
No community posts yet. Be the first to share your experience with Gorlin-Chaudhry-Moss syndrome.
Start the conversation →Latest news about Gorlin-Chaudhry-Moss syndrome
No recent news articles for Gorlin-Chaudhry-Moss syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Gorlin-Chaudhry-Moss syndrome
What is Gorlin-Chaudhry-Moss syndrome?
Gorlin-Chaudhry-Moss syndrome (GCM syndrome) is an extremely rare genetic disorder characterized by a distinctive combination of craniofacial, ocular, dental, and skeletal abnormalities along with hypertrichosis (excessive hair growth). The condition was first described by Gorlin, Chaudhry, and Moss in 1960. Key clinical features include coronal craniosynostosis (premature fusion of skull sutures), midface hypoplasia (underdevelopment of the middle portion of the face), patent ductus arteriosus or other congenital heart defects, eye anomalies such as microphthalmia (abnormally small eyes) and
How is Gorlin-Chaudhry-Moss syndrome inherited?
Gorlin-Chaudhry-Moss syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Gorlin-Chaudhry-Moss syndrome typically begin?
Typical onset of Gorlin-Chaudhry-Moss syndrome is neonatal. Age of onset can vary across affected individuals.